Deep-inspirational breath-hold (DIBH) technique in left-sided breast cancer: various aspects of clinical utility by Gaál, Szilvia et al.
Gaál et al. Radiat Oncol           (2021) 16:89  
https://doi.org/10.1186/s13014-021-01816-3
RESEARCH
Deep-inspirational breath-hold (DIBH) 
technique in left-sided breast cancer: various 
aspects of clinical utility
Szilvia Gaál, Zsuzsanna Kahán, Viktor Paczona, Renáta Kószó, Rita Drencsényi, Judit Szabó, Ramóna Rónai, 
Tímea Antal, Bence Deák and Zoltán Varga*  
Abstract 
Background: Studying the clinical utility of deep-inspirational breath-hold (DIBH) in left breast cancer radiotherapy 
(RT) was aimed at focusing on dosimetry and feasibility aspects.
Methods: In this prospective trial all enrolled patients went through planning CT in supine position under both DIBH 
and free breathing (FB); in whole breast irradiation (WBI) cases prone CT was also taken. In 3-dimensional conformal 
radiotherapy (3DCRT) plans heart, left anterior descending coronary artery (LAD), ipsilateral lung and contralateral 
breast doses were analyzed. The acceptance of DIBH technique as reported by the patients and the staff was ana-
lyzed; post-RT side-effects including radiation lung changes (visual scores and lung density measurements) were 
collected.
Results: Among 130 enrolled patients 26 were not suitable for the technique while in 16, heart or LAD dose con-
straints were not met in the DIBH plans. Among 54 and 34 patients receiving WBI and postmastectomy/nodal RT, 
respectively with DIBH, mean heart dose (MHD) was reduced to < 50%, the heart  V25 Gy to < 20%, the LAD mean dose 
to < 40% and the LAD maximum dose to about 50% as compared to that under FB; the magnitude of benefit was 
related to the relative increase of the ipsilateral lung volume at DIBH. Nevertheless, heart and LAD dose differences 
(DIBH vs. FB) individually varied. Among the WBI cases at least one heart/LAD dose parameter was more favorable in 
the prone or in the supine FB plan in 15 and 4 cases, respectively; differences were numerically small. All DIBH patients 
completed the RT, inter-fraction repositioning accuracy and radiation side-effects were similar to that of other breast 
RT techniques. Both the patients and radiographers were satisfied with the technique.
Conclusions: DIBH is an excellent heart sparing technique in breast RT, but about one-third of the patients do not 
benefit from that otherwise laborious procedure or benefit less than from an alternative method.
Trial registration: retrospectively registered under ISRCTN14360721 (February 12, 2021)
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Background
Radiotherapy has played an essential role in the manage-
ment of breast cancer for decades. Due to the availability 
of modern radiotherapy technologies, significant changes 
have occurred in radiotherapy practice focusing on opti-
mized care on an individual basis [1, 2].
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After breast-conserving surgery most of the patients 
need postoperative whole breast irradiation (WBI) with 
or without a tumor bed boost, while in low-risk cases 
partial breast irradiation (PBI) is sufficient. The need of 
chest wall (CW) irradiation is infrequent unless if com-
bined with nodal irradiation, postmastectomy irradiation 
(PMI). The practice of nodal irradiation shows a broad 
spectrum from the sole irradiation of different axillary 
levels to that of all regional nodes depending on the risk 
status and surgery performed. Clinical studies indicate 
that while after sentinel lymph node biopsy (SNB) axil-
lary block dissection may be replaced with axillary level 
I-II nodal radiotherapy in limited nodal involvement 
cases, full nodal radiotherapy although at a price of radia-
tion sequelae, may contribute to improved survival of 
axillary lymph node positive cases [3, 4].
Most breast cancer patients become long-survivors, 
hence therapeutic interventions should not endanger 
the patients’ general health and well-being. The main 
radiation-related hazards are radiogenic heart and lung 
damage resulting in significant morbidity many years or 
decades after the radiotherapy [5–7]. The excess relative 
risk of secondary lung cancer or cardiac mortality has 
been estimated as 0.11 and 0.04 per one Gray increase of 
the dose to the whole lung and heart, respectively [8, 9]. 
Radiation-induced heart disease (RIHD) most frequently 
manifests in the damage of the coronary and capillary 
vessels of the heart which induces a progressive fibrotic 
process leading to circulatory changes with potentially 
fatal ischemic heart disease (IHD) [10]. The dose-depend-
ent harmful effect of radiation exposure of the heart has 
been demonstrated in retrospective analyses and simu-
lations of radiotherapies of breast cancer (BC) patients 
with IHD [7, 11]. The dose to the heart and hence RIHD 
incidence is higher in left-sided cases and the risk is more 
significant in young patients [12]. It is estimated that 
every 1  Gy mean heart dose increases the incidence of 
IHD event by 7.4% that may be potentiated by preexisting 
cardiovascular risk factors [6, 11] and smoking [8]. In a 
systematic review of contemporary publications, a radia-
tion dose to the heart of 5.2 and 3.7 Gy in left and right 
sided cases, respectively, is still demonstrated while the 
dose to the ipsilateral lung is 9 Gy [8]. The risk of radio-
genic heart damage is linearly dose-dependent, but no 
lower threshold with the absence of risk has been iden-
tified [1]. Hence all efforts should be made to avoid or 
lessen heart exposure as much as possible.
There are many approaches to protect the heart from 
radiation exposure. Prone positioning and the breath-
holding techniques operate by separating the heart and 
the radiation fields; the advanced IMRT and proton 
irradiation techniques are not widely applied, while the 
reduction of the volume to be irradiated during partial 
breast irradiation (PBI) or the omittance of radiotherapy 
are options in low-risk cases. These methods result in 
variable effects on lung and heart exposures: while prone 
radiotherapy dramatically reduces lung doses, heart 
doses individually differ [13–15].
The breath-holding technique first described in breast 
cancer in 2001 [16] only recently became widespread 
[17]. Its greatest impact is reduced dose to the heart 
and LAD, and to a lesser extent to the lung [17, 18]. 
Nevertheless, the magnitude of benefit individually var-
ies according to the patient’s anatomical features and 
lung capacity [18]; occasionally cases with the absence 
of advantage [16] or even elevated heart doses [19] have 
been described. Since earlier we found prone position-
ing individually helpful for heart sparing in the RT of 
Fig. 1 Three-dimensional conformal whole breast irradiation plans of 2 cases illustrating the benefit (upper series) or the lack of benefit (lower 
series) of the DIBH manoeuvre; transversal slices are shown during free-breathing (FB), DIBH and in the prone position (PTV contoured in red, heart 
contoured in orange, LAD contoured in yellow)
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left breast cancer cases (13–15), we wished to study the 
practical aspects of DIBH to find out its optimal place in 
routine practice. We tested the feasibility of the method 
among all patients, analyzed the relative dosimetry ben-
efits according to the indications, and in the WBI only 
cohort, analyzed nodal coverage; also, radiation lung 
changes were prospectively followed.
Methods
This prospective cohort study had been approved by the 
Institutional Ethics Review Board of the University of 
Szeged (#272/2017), and all the enrolled patients gave 
their written informed consent to participation. Inclusion 
criteria were left-sided breast cancer needing postopera-
tive WBI/PMI and informed consent, while the exclusion 
criteria were the presence of chronic obstructive pulmo-
nary disease, bronchial asthma or other severe comorbid-
ity that would hinder cooperation during DIBH (extreme 
obesity, mental disorder, hypacusis).
For DIBH, the protocol of the voluntary breath-holding 
technique as described by Bartlett et al. was followed [20; 
http:// www. jove. com/ video/ 51578/]. All enrolled patients 
were assessed for baseline breath-holding capacity and 
trained for DIBH by a physiotherapist (JS), who reinvited 
the patient for further support if needed. Those patients 
who could not practise breath-holding for a minimum of 
20  s were withdrawn from DIBH. These, together with 
those who despite sufficient breath-hold did not have 
improved heart and/or LAD doses (and hence DIBH was 
irrelevant) were excluded from further analyses.
Planning CT series were acquired in supine position 
with the arms elevated under both normal breathing and 
DIBH; in WBI cases CT was performed also in prone 
position. In-room lasers, skin marks, and verbal instruc-
tions through an audiovisual system with high perfor-
mance video cameras (RMC-190 controller, 2 PTC-120 
robotic HD cameras, Datavideo Technologies Co., Tai-
wan) ensured consistent breath-hold; beam-gating was 
applied manually.
Target volumes and organs at risk (OARs) were out-
lined in all CT series, and treatment plans were gener-
ated in all setups. In the first series of 37 cases irradiated 
with DIBH technique, portal imaging 3-times a week 
with 2 orthogonal setup beams of kilovoltage photon 
energy was performed, necessary couch translations 
were recorded and inter-fractional systematic and ran-
dom setup errors were calculated; also, daily treatment 
times were recorded, and questionnaires regarding the 
comfort of the RT procedure (patients, RT fractions 6 
and 25, cumulative score 0–9) and the efforts needed 
from the staff during planning CT or RT (radiographers, 
planning CT and RT fractions 6 and 25, cumulative score 
0–12) similarly to Bartlett et  al. were completed [20]. 
High scores indicated satisfactory acceptance (Additional 
file 1).
Radiotherapy and dosimetry data
Radiotherapy techniques and facilities were described 
previously [13–15]. Briefly, patients were positioned 
on the supine thorax and prone breast modules (WBI 
cases) of the AIO (All In One) Solution (ORFIT, Wij-
negem, Belgium) system without mask fixation. Plan-
ning CT images were acquired throughout the entire 
planning volume. Target volumes (whole breast or chest 
wall with or without nodal regions including axillary lev-
els I-IV and internal mammary lymph nodes) and OARs 
i.e. the heart, LAD, ipsilateral lung, contralateral breast 
were contoured according to the European Society for 
Radiotherapy and Oncology (ESTRO) guidelines [21]. 
The aim was to achieve equivalent target and nodal vol-
ume contouring among all setups. The main objectives 
were a mean dose to the planning target volume (PTV) 
of 50 Gy (25 fractions), and  V47,5 Gy ≥ 90%,  V53,5 Gy ≤ 1%, 
while the dose constraints were the following: heart mean 
dose < 2.5  Gy,  heartV25Gy < 3%, LAD mean dose: < 12  Gy, 
lung mean dose < 10  Gy (WBI) and < 16  Gy (nodal RT), 
lung  V20 Gy < 15% (WBI) and 30% (nodal RT), contralat-
eral breast  V10Gy < 5%. All plans were generated in the 
Varian Eclipse v13.6 (Varian Oncology Systems, Palo 
Alto, CA, USA) treatment planning system with the Ana-
lytical Anisotropic Algorithm (AAA) v8.0. 3DCRT plans 
applyed opposing tangential 6MV photon fields set up 
isocentrically and a median of 2 (1–3) 6/10 MV segmen-
tal fields (WBI, CW) (Fig. 1). For nodal irradiation, a sin-
gle matched field was used. Sequential tumor bed boosts 
given according to the protocol were not included in the 
dosimetric comparisons. Radiotherapy was delivered 
with a Varian TrueBeamSTx (Varian Oncology Systems, 
Palo Alto, CA, USA) linear accelerator.
For plan evaluation, conformity and homogeneity indi-





(TV: Target volume, i.e. PTV;  TVRI: Target volume cov-
ered by the reference isodose;  VRI: Volume of the refer-
ence isodose, ideal is 1),
Homogeneity Index (HI) [16]  (D2%,  D50%,  D98% = dose 
received by 2%, 50% and 98% of PTV, respectively, ideal 
is 0):
The following dose-volume parameters of the PTV 
and OARs were collected: heart mean dose, heart  V25 Gy, 
LAD mean dose, LAD maximum dose, ipsilateral mean 
lung dose, ipsilateral lung  V20 Gy, contralateral breast  V10 
Gy. In further analyses we compared heart and LAD dose 
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heart  V25 Gy and LAD mean dose in RT plans under FB vs. 
DIBH, respectively) with the relative increase of the ipsi-
lateral lung volume.
In the WBI only cohort, nodal regions were retrospec-
tively contoured both in the DIBH and free breathing 
(FB) planning CTs for nodal dosimetry  (V25 Gy,  V45 Gy, 
 V47.5 Gy) comparisons [21, 23].
Follow‑up of patients including lung density change 
measurements
Data on clinical symptoms, skin changes and breast 
fibrosis were collected in the first cohort of patients at 
the completion of RT, and 3 months and 1 year thereafter 
using the CTCAE v. 4 system. Also, chest CTs under FB 
were performed at these time points for assessing post-
irradiation lung changes as described [24]. Briefly, CT 
scans were evaluated both visually (category 0: no visible 
changes, category 1: increased density, hazy opacity, cat-
egory 2: strand-like thickening) and with measuring the 
density of the lungs in a CT slice at the level of the left 
heart ventricle in the area outlined by the chest wall and 
a line between the edge of the sternum and the midheight 
of the chest in comparison with the planning CT. Den-
sity measurements were performed by excluding visible 
changes, and were corrected by subtracting the density 
of the unexposed contralateral lung. Visual assessment 
scores and mean lung density changes (MLDC) were ana-
lyzed and compared to the same parameters in a previous 
cohort of patients irradiated between 2010 and 2011 with 
3DCRT under FB in supine position.
Statistical analysis
Patient-related and dosimetry data were summarized 
using descriptive statistics; quantitative variables were 
expressed as mean ± SD. For the comparison of data, 
repeated ANOVA test (3 variables) and paired t-test (2 
variables) were used. Lung density changes were ana-
lyzed with one-way ANOVA, while visual scores in the 
DIBH vs. FB groups with the chi-square test. The effects 
of patient-related variables or RT categories on DIBH-
related dosimetry benefit were evaluated with linear 
regression.
Results
According to the inclusion and exclusion criteria, 
130 patients were enrolled between January 2018 and 
November 2019, nevertheless, among them 42 patients 
did not partake in DIBH and hence were not included 
in the dosimetry analysis of DIBH cases. Twenty-six 
patients were not suitable for DIBH (18 could not with-
hold breathing for 20 s, 3 patients were stressed, 2 with-
drew consent, 1 could not follow the instructions, 1 
was diagnosed with pulmonary embolism following 
enrollment and 1 with disease progression), while in 16 
cases OAR doses were apparently not acceptable despite 
the DIBH manoeuvre. Out of the 16 patients with subop-
timal 3DCRT plans under DIBH, 10 received RT with an 
alternative technique in supine position, and 6 received 
3DCRT in prone position. Altogether 88 patients 
received RT under DIBH, their age was 57.3 ± 11.7 years 
(mean ± SD), their weight, length and BMI were 
72.5 ± 13.6  kg, 163.6 ± 7.1  cm and 27.1 ± 5.1  kg/m2 
(mean ± SD), respectively. Among them 35 received 
chemotherapy before the RT, and 56 received endocrine 
therapy during (aromatase inhibitors) or after (tamox-
ifen) the RT.
Dosimetry data
In the group of 88 patients who received 3DCRT under 
DIBH, MHD was reduced by > 50%, the heart  V25 Gy 
by > 80%, the LAD mean dose by > 60% and the LAD 
maximum dose by about 50% as compared to that under 
FB (Table  1). The extent of dose reduction did not dif-
fer according to the indication of WBI, PMI or nodal 
RT. Lung doses were lower under DIBH than under FB 
and were dramatically reduced in the prone RT plans. 
The dose to the contralateral breast did not significantly 
change according to DIBH vs. FB. Nevertheless, heart 
and LAD dose differences (DIBH vs. FB) individually var-
ied. Among the WBI cases at least one dose parameter 
was more favorable in the prone plan or in the supine 
WBI + FB plan in 15 or 4 cases, respectively; differences 
were numerically small (Table  2/A). None of the heart 
or LAD doses were superior under FB in the group of 
patients receiving WBI/CW + nodal RT. As mentioned 
earlier, in altogether 16 cases of all enrolled patients dose 
constraints were not met in the supine 3DCRT + DIBH 
plans; these patients received irradiation using an alter-
native technique with improved dose parameters as listed 
in Table 2/B.
The relative increase in the volume of the ipsilateral 
lung was 1.75 ± 0.06 (range 1.25–2.41).
Weak correlations were found in the entire DIBH popu-
lation between the relative increase of the ipsilateral lung 
volume and the MHD (R = 0.400, p < 0.000), heart  V25Gy 
(R = 0.386, p < 0.001) and LAD mean dose (R = 0.242, 
p = 0.037). None of the studied patient-related or RT 
parameters were associated with the benefit of DIBH.
In a dosimetry analysis, we studied the nodal doses 
in a cohort of 30 WBI cases under FB vs. DIBH. WBI 
with DIBH delivered significantly less dose to the level 
1 axillary lymph nodes but larger doses to the interpec-
toral and internal mammary nodes than WBI under FB 
(Table  4). Although the average  V45 Gy was < 30% in all 
subregions, individual dose coverage differed (Table 3).
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Feasibility
All the patients having started DIBH completed the 
treatment. Inter-fractional random and systematic setup 
errors were 3.9 and 2.7  mm, respectively. The average 
and median time for daily radiotherapy with DIBH took 
mean: 10.7 (7–19) minutes.
In 43 cases including 27 patients with WBI only, 4 
with WBI + nodal RT and 12 with CW + nodal RT, 
post-RT follow-up data were analyzed (Table 4). Radio-
dermatitis of grade 1 was usual breast fibrosis occurred 
in 40% of the patients 3  months after the RT but was 
much less thereafter. Asymptomatic inflammatory/
fibrotic radiogenic lung changes were present in most 
cases, while in 2 patients also chest pain and cough 
developed, but medical intervention was not needed 
(pneumonitis of grade 1) (Table 4/A). Visual assessment 
and MLDC data were compared to the same parameters 
of a cohort of patients having received WBI in the 
supine position under FB in 2010–2011; no significant 
difference was detected (Table  4/B). Good agreement 
between visual scores and MLDC values 3 months after 
RT was found; no association was detected with the rel-
ative change of the ipsilateral lung volume.
During the RT of the first 37 patients, both patients 
and technicians evaluated the feasibility and easiness 
of the DIBH technique by completing a questionnaire. 
Patients were asked about their comfort during the 
DIBH procedure, the stability of the position and the 
easiness of the intervention, while radiographers were 
asked about their efforts needed and the compliance 
of the patient during intervention. High total scores 
indicate satisfaction with the method from both sides 
(Table 5).
Table 2 Heart and LAD doses in patients for whom DIBH did not provide advantage
WB, whole breast, CW, chest wall, WBI, whole breast irradiation, IMRT, intensity-modulated radiotherapy, 3DCRT, 3D conformal radiotherapy
A, Patients treated with 3DCRT + DIBH (n = 88): the difference in heart and LAD doses (DIBH vs. FB/prone) differed according to the case and the dosimetry parameter
B, List of individual dose differences among the 16 patients excluded from DIBH due to unacceptable heart and LAD doses; in these, alternative RT techniques were 
used as indicate
n = 88 WBI (n = 54) WBI/CW + nodal 
(n = 34)
FB equal/better than DIBH Prone equal/better than DIBH FB equal/better than 
DIBH
mean difference (range) n mean difference (range) n mean difference 
(range)
n
Mean heart dose (Gy) 0.63 (0.63–0.63) 1 0.36 (0.00–0.89) 7 – 0
Heart V25Gy (%) 0.59 (0.00–1.19) 2 0.44 (0.00–1.88) 15 – 0
LAD mean dose (Gy) 0.53 (0.14–1.62) 5 1.91 (0.00–5.10) 7 – 0
LAD max dose (Gy) 6.18 (3.61–8.76) 2 8.16 (0.11–16.15) 6 – 0
Patient # Target volume Technique Heart mean dose (Gy) Heart V25Gy (%) LAD mean dose (Gy) LAD max dose (Gy)
DIBH FB Prone DIBH FB Prone DIBH FB Prone DIBH FB Prone
1 WB IMRT 2.75 6.99 3.87 2.94 11.79 5.02 14.99 22.84 19.73 49.96 50.45 48.66
2 WB Prone 2.06 4.68 0.97 2.15 3.45 0 10.99 12.42 3.8 32.23 48.09 8.52
3 WB Prone 2.96 2.98 1.66 2.63 2.55 0.02 18.84 20.53 3.75 46.73 45.83 22.19
4 WB Prone 5.54 5.98 1.19 8.25 9.21 0 20.73 19.66 3.45 48.73 48.53 11.64
5 WB Prone 3.42 5.16 1.39 4.92 8.79 0.03 24.23 37.43 3.52 49.11 50.37 9.66
6 WB Prone 3.33 4.57 1.06 5.44 7.63 0 22.42 25.18 3.45 48.28 48.31 6.76
7 WB Prone 5.34 5.43 1.39 10.37 10.05 0.28 21.55 19.29 5.83 50.7 49.97 31.57
8 WB/CW + nodal IMRT 3.58 3.91 4.09 4.88 30.87 28.64 46.69 46.27
9 WB/CW + nodal IMRT 4.18 7.56 5.11 12.27 21.66 26.59 46.71 49.06
10 WB/CW + nodal IMRT 6.55 8 9.32 12.57 38.07 40.37 48.61 47.07
11 WB/CW + nodal IMRT 5.59 9.46 7.78 16.49 23.94 21.46 48.11 48.95
12 WB/CW + nodal 3DCRT 7.93 6.81 13.51 11.67 15.32 17.16 50.63 49.71
13 WB/CW + nodal 3DCRT 10.51 11.66 18.59 21.04 27.25 36.56 51.07 50.53
14 WB/CW + nodal 3DCRT 6.69 7.19 10.71 11.86 36.99 38.8 50.84 51.43
15 WB/CW + nodal 3DCRT 5.56 6.06 8.69 9.71 17.06 17.28 48.48 47.27
16 WB/CW + nodal IMRT 7.81 6.81 13.88 11.85 36.54 39.63 51.23 51.6
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Discussion
DIBH could not be implemented for all patients. We 
found that even among patients seemingly appropri-
ate for the technique, about 20% could not practise 
DIBH, and 15% of the rest due to dosimetry concerns 
had to receive RT using an alternative technique. Fur-
thermore, although in the remaining cases the DIBH 
maneuver resulted in reduced heart and LAD and lung 
doses in most, still, in some cases FB or prone position-
ing yielded superior or equal dosimetry results.
In a large database of 272 patients, similar experience 
was found: more than 40% of the patients were not suit-
able for or did not benefit from 3DCRT + DIBH [25]. 
Tanguturi et al. found that among 146 patients deemed 
potential candidates for breast radiotherapy with DIBH, 
the DIBH technique provided a neutral change in 25 
(17%) or even increased MHD in 14 (10%) cases. A ben-
eficial effect was favored by younger age, greater body 
mass index (BMI) and larger inspirational lung volume 
changes [26]. Dell’Oro et al. demonstrated that the ben-
efit provided by DIBH in OAR doses individually dif-
fers. Notably, 3 out of 20 patients had higher heart, 4 
had increased LAD and 6 had increased lung doses 
under DIBH as compared to FB [19]. It was found that 
larger total lung volume increase predisposed to more 
significant DIBH-related heart and LAD dose reduc-
tions. Lin et al. found that in comparison to FB, DIBH 
resulted larger benefit in heart and LAD doses during 
postmastectomy RT than during WBI [27]. No similar 
relationship could be seen in our study; in this patient 
cohort heart and LAD dose reductions were weakly 
correlated with DIBH-related lung volume increases, 
and none of the studied parameters seemed to have 
predictive power.
Due to the mentioned obstacles of benefiting the most 
from DIBH and for the optimal use of resources, every 
RT center should decide its strategy how to include DIBH 
into routine practice. One approach is the use of anatom-
ical attributes for individual patient selection. Lin et  al. 
tested artificial intelligence-based predictive models to 
choose the preferred RT technique DIBH vs. prone in a 
set of 16 patients needing WBI. Taking into consideration 
heart doses only, breast volume and the distance between 
the center of the breast and the heart, while respecting 
composite OAR exposure including the ipsilateral lung, 
the volumes of the heart and breast, and breast-lung dis-
tance had predictive power [27]. If just heart doses were 
considered, in more cases was preferred the DIBH tech-
nique, while if weighted OAR toxicity (dose to heart, ipsi-
lateral lung, and contralateral breast) was considered, the 
opposite was the finding.
Another possibility is to apply DIBH only in a selected 
group of patients for example if heart exposure seems 
unfavorable under FB. Such an optimization-selection 
approach was the development of a trained model (using 
RapidPlan™, Varian) to develop RT preplans for the esti-
mation of heart doses under FB: if the parameters under 
FB are satisfying, there is no need for a second series 
of CT under DIBH [28]. Another strategy to perform 
screening of all left-sided cases for DIBH using a quick, 
pragmatic, and systematic assessment protocol by radiog-
raphers to consider whether the technique is beneficial, 
and the patient is suitable [25]. In both cases, primary CT 
scanning under FB was needed. Tanna et al. compared 4 
selection methods, and found optimal the London Can-
cer Alliance’s upfront selection process (without the need 
of CT scanning under FB) that recommends the use of 
DIBH if the tumor bed is situated in the lower quadrants 
Table 3 Nodal coverage among the WBI cases under FB vs. with 
DIBH
FB, free breathing; DIBH, deep inspirational breath hold
n = 30 Nodal subregion FB DIBH p
Volume  (cm3) Axillary Level 1 51.8 ± 28.3 51.9 ± 28.4 0.692
Subpectoral 11.3 ± 3.7 11.3 ± 4.0 0.824
Interpectoral 5.0 ± 2.8 5.1 ± 2.8 0.204
Axillary Level 3 10.5 ± 3.0 10.4 ± 3.3 0.451
Axillary Level 4 13.6 ± 3.3 13.5 ± 3.2 0.422
Internal Mammary 1.5 ± 0.4 1.4 ± 0.4 0.004
Mean dose (Gy) Axillary Level 1 29.5 ± 9.2 26.1 ± 9.4 0.005
Subpectoral 7.7 ± 5.1 7.8 ± 5.5 0.903
Interpectoral 26.3 ± 10.2 30.2 ± 9.1 0.024
Axillary Level 3 3.2 ± 2.3 3.6 ± 3.8 0.538
Axillary Level 4 0.8 ± 0.2 0.8 ± 0.2 0.209
Internal Mammary 13.5 ± 8.3 17.3 ± 10.6 0.008
V > 25 Gy (%) Axillary Level 1 60.2 ± 23.1 51.7 ± 22.6 0.005
Subpectoral 10.0 ± 11.4 10.7 ± 13.0 0.716
Interpectoral 55.6 ± 24.2 63.9 ± 22.4 0.036
Axillary Level 3 2.0 ± 3.7 3.0 ± 7.5 0.422
Axillary Level 4 0.0 0.0 –
Internal Mammary 19.8 ± 21.3 29.9 ± 27.4 0.007
V > 45 Gy (%) Axillary Level 1 31.3 ± 19.6 27.2 ± 20.3 0.169
Subpectoral 0.5 ± 2.2 0.3 ± 1.0 0.705
Interpectoral 17.1 ± 18.2 25.2 ± 23.9 0.068
Axillary Level 3 0.1 ± 0.3 0.1 ± 0.2 0.795
Axillary Level 4 0.0 0.0 –
Internal Mammary 6.4 ± 14.9 12.3 ± 20.1 0.065
V > 47.5 Gy (%) Axillary Level 1 13.2 ± 13.8 13.0 ± 15.1 0.932
Subpectoral 0.1 ± 0.1 0.0 0.326
Interpectoral 5.0 ± 13.2 8.3 ± 16.5 0.223
Axillary Level 3 0.0 0.0 –
Axillary Level 4 0.0 0.0 –
Internal Mammary 3.8 ± 11.1 5.8 ± 11.6 0.111
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of the breast or is extensive, and in all CW RT cases [29]. 
This method should be preferred in centers with resource 
constraints.
In most cases similar heart and LAD dose reductions 
to published results were found at DIBH [17, 18, 20]. 
We consider DIBH one of the heart sparing techniques 
which, has the mainstay of good reproducibility and the 
position-stabilization of the PTV [30]. In WBI cases 
an alternative solution could be prone positioning; in 
this, although repositioning accuracy is inferior, ipsi-
lateral lung dose is significantly reduced. In nodal RT 
cases, if DIBH cannot be utilized, the IMRT technique 
may provide solution. Actually, Zhao et  al. found that 
unacceptable heart and LAD doses in 3DCRT plans with 
DIBH could be solved using the IMRT technique, but no 
further dosimetric improvement was seen in low OAR-
dose cases [31]. In fact, the consideration of the dose 
constraints of the heart and its substructures seems the 
most important for adequate heart sparing in modern RT 
as suggested by the DEGRO breast cancer expert panel; 
the appropriate technique should be selected accordingly 
[32].
Thanks to the successful use of new technologies and 
raised attention to solving heart sparing, the control of 
ipsilateral lung doses is becoming a challenge. It has been 
estimated that DIBH by reducing the dose to the ipsilat-
eral lung volume and lung mass by 15–24%, results in an 
about 20% improvement in lung normal tissue complica-
tion probability (NTCP) as compared to that after FB [33, 
34]. In fact, lung doses approximate zero if prone WBI is 
performed. Yan et al. based on literature data, compared 
the risks of cardiac death, significant cardiac event, or 
lung cancer mortality in 34 breast cancer patients hav-
ing RT plans both under DIBH and in the prone posi-
tion. Both techniques provided excellent cardiac sparing, 
nevertheless, with DIBH, an excess lung cancer mortality 
of 0.5% evolved, which was absent with the prone WBI 
technique [35]. We studied the occurrence of acute and 
late radiation changes of the ipsilateral lung by means 
of visual evaluation and lung density measurements. 
That special interest was due to the known stimulatory 
effect of oxygen on radiosensitivity. The incidence of 
Table 4 Radiogenic side effects at the end of RT under DIBH and 3 months or 1 year thereafter
MLDC: mean lung density changes
A, Toxicity was assessed according to the CTC AE vs. 4 system
B, Lung density changes by means of visual assessment and lung density measurements were compared to the same parameters of a historical cohort of patients 




3 months after RT (n = 43) 12 months after RT (n = 35)
Pneumonitis Dermatitis Breast fibrosis Pneumonitis Dermatitis Breast fibrosis
(A)
0 3 41 14 26 35 30 29
1 33 2 29 15 0 5 4
2 7 0 0 2 0 0 2
3 months after RT p (ANOVA) 12 months after RT p (ANOVA)
n (%) MLDC n (%) MLDC
(B)
3DCRT + DIBH visual score 0 6 (14.0) 12.0 ± 38.4  < 0.001 8 (22.9) 37.3 ± 83.1 0.119
Visual score 1 20 (46.5) 49.4 ± 41.4 15 (42.9) 49.6 ± 30.6
Visual score 2 17 (39.5) 126.4 ± 54.9 12 (34.2) 95.7 ± 92.5
3DCRT + FB visual score 0 7 (28.0) 32.4 ± 32.6 0.035 6 (40.0) 20.3 ± 53.5 0.522
Visual score 1 11 (44.0) 43.1 ± 19.3 6 (40.0) 33.5 ± 21.8
Visual score 2 7/25 (28.0) 71.4 ± 32.1 3 (20.0) 53.7 ± 37.8
Table 5 Acceptance of the DIBH method by the patient (at the 
occasions of RT fractions 6 and 25) and the radiographer (at the 
occasions of planning CT and RT fractions 6 and 25) was scored 
in 37 cases; the patients answered the same 3 questions, the 
radiographers the same 4 questions each time. Score 0: worst, 
score 3: best; scores to specific questions were added up
n = 37 Patient (maximum 
score: 9)












Mean ± SD 7.9 ± 1.3 7.4 ± 1.5 9.9 ± 2.1 9.2 ± 2.1 9.5 ± 1.8
Median 8 7 10 9 10
Range 5–9 5–9 4–12 5–12 5–12
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asymptomatic abnormalities was higher, but not sig-
nificantly different from that in an earlier patient cohort 
(Table 4/B). We believe that the protocol-defined follow-
up period of 1  year post-radiotherapy was sufficient to 
detect all adverse pulmonary reactions.
A significant proportion of the enrolled patients was 
not able to effectively practise DIBH. Those whose vol-
untary breath-holding capacity or chest wall movements 
were not sufficient for DIBH were identified before or at 
simulation. In a retrospective analysis, Nissen et al. found 
similar proportion and similar reasons for omitting DIBH 
in a left-sided BC patient population: among 20 patients 
non-compliant to DIBH, 7 could not use the equipment, 
7 was not able to maintain breath-hold for at least 20 s, 
7 had psychological problems, and 4 had other reasons 
[36]. Training for DIBH is essential. Kim et  al. detected 
lower heart doses in patients who received 5-day pre-
paratory coaching before starting DIBH versus those 
who did not [36]. There is controversy whether thoracic 
or abdominal DIBH provides better heart sparing [31]. 
Zhao et  al. found that most patients practice thoracic 
DIBH, but may be easily trained for abdominal DIBH 
which in fact, better lowers heart, LAD and lung doses 
[31]. Proper DIBH technique is essential since its benefi-
cial effect depends primarily on the lung volume increase 
achieved [19, 26]. We consider very important the role 
of the physiotherapist expert who should provide stand-
ardized coaching and support to the patients. The DIBH 
technique was easily adapted, and inter-fractional repo-
sitioning accuracy seemed similar to that of other tech-
niques (supine, prone, PBI).
As demonstrated by Pazos et  al. and Borm et  al. [37, 
38], during DIBH, the relative position of the nodal 
regions to that of the PTV changes and as a consequence 
accidental doses to axillary levels I and II become less or 
more relevant as compared to that without DIBH. We 
separately analyzed the 6 nodal regions, and found that 
due to DIBH while the dose to axillary level I is lower, 
the doses to the interpectoral lymph node region and the 
ipsilateral internal mammary (IM) region may be higher 
than during FB, however, differences show individual var-
iations. We think that this finding should raise attention 
to always considering the doses to axillary levels I-II if 
their irradiation is needed due to limited axillary surgery 
and low-volume SNB positivity. In these cases, supine RT 
with DIBH should be favored instead of prone WBI since 
during the latter the axillary lymph node regions are 
excluded from irradiation [23].
Since the dose to the OARs is rarely a problem during 
PBI, limited experience is published with PBI and DIBH 
[37]. The DIBH method utilized independently of the lat-
erality of the disease was found useful for the PBI of 37 
patients [39]. In our practice, heart and LAD exposure 
clearly depended on the size and location of the tumor 
bed. Recently, the use of DIBH occasionally, in cases with 
relatively high heart or LAD doses in PBI plans the DIBH 
method provided prompt solution.
Conclusions
DIBH is one of the powerful heart sparing techniques in 
breast cancer RT. Alertness is needed to identify those 
patients who do not benefit from that laborious proce-
dure or benefit less than from an alternative method: if 
WBI is needed, prone positioning, if nodal RT is neces-
sary the IMRT technique could be alternate options.
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